Cargando…

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet

AIMS: The aims of this study were to develop a pharmacokinetic (PK) and PK‐pharmacodynamic (PK/PD) model of cinacalcet in adults and paediatrics with secondary hyperparathyroidism (SHPT) on dialysis, to test covariates of interest, and to perform simulations to inform dosing in paediatrics with SHPT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ping, Sohn, Winnie, Narayanan, Adimoolam, Gisleskog, Per Olsson, Melhem, Murad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533487/ https://www.ncbi.nlm.nih.gov/pubmed/30756425 http://dx.doi.org/10.1111/bcp.13900

Ejemplares similares

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Cinacalcet in HIV haemodialysis patients
por: Belmouaz, Simohamed, et al.
Publicado: (2008)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF
por: Harrold, John, et al.
Publicado: (2020)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial
por: Liu, Lin, et al.
Publicado: (2020)

A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
por: Eddington, Helen, et al.
Publicado: (2021)

An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
por: Sohn, Winnie Y., et al.
Publicado: (2018)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Successful Early Treatment of Severe Neonatal Hyperparathyroidism With Cinacalcet
por: Thakkar, Keya, et al.
Publicado: (2021)

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study
por: Rottembourg, Jacques, et al.
Publicado: (2019)

Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
por: Rottembourg, Jacques, et al.
Publicado: (2018)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients
por: Fisher, Marisa M, et al.
Publicado: (2015)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Cinacalcet: A Viable Therapeutic Option for Primary Hyperparathyroidism in the Elderly
por: Abusahmin, Hussam, et al.
Publicado: (2018)

Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis
por: Dulfer, R. R., et al.
Publicado: (2019)

The conundrum of parathyroidectomy vs cinacalcet for treatment of post-transplant hyperparathyroidism
por: Patel, Rima, et al.
Publicado: (2020)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
por: Mawad, Habib, et al.
Publicado: (2017)

Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience
por: Mogl, M. T., et al.
Publicado: (2020)

A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism
por: Bell, Daniel, et al.
Publicado: (2021)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome
por: Harrold, John, et al.
Publicado: (2020)

Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature
por: Vera, Lara, et al.
Publicado: (2016)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function
por: Nguyen, Son, et al.
Publicado: (2020)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

SAT-349 Cinacalcet Resistant Tertiary Hyperparathyroidism with One Large Parathyroid Gland
por: Chaker, Bayan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_89urg4k2j92opf5pj89fl70od6